{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T16:12:09Z","timestamp":1778256729767,"version":"3.51.4"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s574169","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:40:14Z","timestamp":1778254814000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic Physiologically Based Pharmacokinetic Modeling to Predict CYP3A4-Mediated Drug\u2013Drug Interactions of Flumatinib as Both a Victim and a Perpetrator"],"prefix":"10.2147","volume":"Volume 20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-8844","authenticated-orcid":true,"given":"Muyesaier","family":"Alifu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5248-721X","authenticated-orcid":true,"given":"Xinyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Yao","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aole","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-1550","authenticated-orcid":true,"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-5564","authenticated-orcid":true,"given":"Zheng","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-2603","authenticated-orcid":true,"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s0140-6736(07)61165-9","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/s0140-6736(21)01204-6","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","volume":"9","author":"Ning","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12185-015-1893-y","volume":"103","author":"Mendizabal","year":"2016","journal-title":"Int J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","volume":"14","author":"Malik","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref7","first-page":"721","volume":"30","author":"Wang","year":"2009","journal-title":"Zhonghua xue ye xue za zhi"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/leu.2010.169","volume":"24","author":"Luo","year":"2010","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1101738","DOI":"10.3389\/fonc.2023.1101738","volume":"13","author":"Jiang","year":"2023","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.Ccr-20-1600","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref11","unstructured":"(NMPA) NMPA. Flumatinib mesylate approved for the treatment of chronic myeloid leukemia. Available from: https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/\/zhuanti\/cxylqx\/cxypxx\/20191126142301880.html. Accessed September 11, 2024."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1691\/ph.2020.0068","volume":"75","author":"Chen","year":"2020","journal-title":"Die Pharmazie"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1168852","DOI":"10.3389\/fphar.2023.1168852","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref14","unstructured":"(NMPA) NMPA. Flumatinib mesylate tablets: prescribing information. Available from: https:\/\/cn.hspharm.com\/upload\/file\/2023\/03\/06\/3799f766d8f4494aa0a44bd073f05bb0.pdf. Accessed September 15, 2024."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1208\/s12248-008-9027-6","volume":"10","author":"Polli","year":"2008","journal-title":"AAPS J"},{"key":"ref17","unstructured":"Administration FaD. M12 drug interaction studies guidance for industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m12-drug-interaction-studies. Accessed Feb 05, 2025."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/cts.12987","volume":"14","author":"Tang","year":"2021","journal-title":"Clin Transl Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1124\/dmd.123.001373","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-017-0976-0","volume":"40","author":"Min","year":"2017","journal-title":"Arch Pharm Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00280-023-04566-z","volume":"92","author":"Wang","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref22","unstructured":"Administration USFD. Physiologically based pharmacokinetic analyses\u2014format and content. Available from: https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs. Accessed May 20, 2025."},{"key":"ref23","unstructured":"European Medicines Agency: London U. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2018."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060737","volume":"16","author":"Yin","year":"2024","journal-title":"Pharmaceutics"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/psp4.12682","volume":"10","author":"De Zwart","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref26","volume":"27","author":"Song","year":"2016","journal-title":"J Qiqihar Med Univer"},{"key":"ref27","first-page":"4","volume":"91","author":"Zhong","year":"2011","journal-title":"Chinese Med J"},{"key":"ref28","volume-title":"Pharmacokinetics and Metabolism of Flumatinib in Patients with Chronic Myeloid Leukemia","year":"2010"},{"key":"ref29","first-page":"42","volume":"1","author":"Zhimin","year":"1995","journal-title":"Transactions of Tianjin University"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","volume":"22","author":"Schmitt","year":"2008","journal-title":"Toxicol in vitro"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"106757","DOI":"10.1016\/j.ejps.2024.106757","volume":"196","author":"Zheng","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00280-020-04117-w","volume":"86","author":"Kuang","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1124\/dmd.110.032326","volume":"38","author":"Gong","year":"2010","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/114971","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/114971","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:40:14Z","timestamp":1778254814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/mechanistic-physiologically-based-pharmacokinetic-modeling-to-predict--peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/dddt.s574169","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}